What?A 25% one year survival rate? Was that the stellar news we have been waiting for? A big let down for me. Am I missing something here? Now I better understand the second phase three trial. Saving 25% of the worst of the worst is less then I expected. Treating all patients with this vaccine as a first line of defense is where this study is taking us. Still hanging in there, T-booth.